With the expiry of Januvia's patent on the 1st of next month, the three-drug combination is expected to be launched in earnest in the domestic oral diabetes treatment market.

In particular, since the revised reimbursement standard in April recognizes only three drugs, it is noteworthy whether the three-drug complex with improved ease of use will become mainstream. According to the industry on the 20th, the material patent for DPP4-type diabetes treatment Januvia will expire on September 1. As a result, Januvia's generics are expected to emerge. This is because the market size of the domestic Januvia series alone reaches 157.6 billion won (based on UBIST in 2022).

In particular, the 3-com